131 related articles for article (PubMed ID: 36452965)
1. Clinicopathologic Features and the Loss of ARID1A Expression in Ovarian Seromucinous Borderline Tumors and Seromucinous Carcinomas.
Ok Atılgan A; Özen Ö; Haberal Reyhan AN; Ayhan A
Int J Surg Pathol; 2023 Jun; 31(4):398-408. PubMed ID: 36452965
[TBL] [Abstract][Full Text] [Related]
2. PAX2, PAX8, and PR are correlated with ovarian seromucinous borderline tumor with endometriosis.
Yun BS; Won S; Kim JH; Lee N; Kim M; Kim MK; Kim ML; Jung YW; Kim JY; Seong SJ; Shin E
J Ovarian Res; 2022 Apr; 15(1):41. PubMed ID: 35387670
[TBL] [Abstract][Full Text] [Related]
3. [Expression of ARID1A in ovarian seromucinous neoplasms and its clinicopathological significance].
Ding XH; Tian X; Wang LQ; Wang Y; Liu AJ
Zhonghua Bing Li Xue Za Zhi; 2020 Jun; 49(6):588-593. PubMed ID: 32486536
[No Abstract] [Full Text] [Related]
4. Endocervical-type mucinous borderline tumors are related to endometrioid tumors based on mutation and loss of expression of ARID1A.
Wu CH; Mao TL; Vang R; Ayhan A; Wang TL; Kurman RJ; Shih IeM
Int J Gynecol Pathol; 2012 Jul; 31(4):297-303. PubMed ID: 22653341
[TBL] [Abstract][Full Text] [Related]
5. Ovarian seromucinous carcinoma: report of a series of a newly categorized and uncommon neoplasm.
Taylor J; McCluggage WG
Am J Surg Pathol; 2015 Jul; 39(7):983-92. PubMed ID: 25723110
[TBL] [Abstract][Full Text] [Related]
6. Seromucinous ovarian tumor A comparison with the rest of ovarian epithelial tumors.
Karpathiou G; Chauleur C; Corsini T; Venet M; Habougit C; Honeyman F; Forest F; Peoc'h M
Ann Diagn Pathol; 2017 Apr; 27():28-33. PubMed ID: 28325358
[TBL] [Abstract][Full Text] [Related]
7. Three cases of seromucinous carcinoma of the ovary arising in endometriotic cysts.
Taga Y; Chigusa Y; Minamiguchi S; Kido A; Horikawa N; Horie A; Hamanishi J; Kondoh E; Mandai M; Yamaguchi K
Int Cancer Conf J; 2021 Jan; 10(1):46-53. PubMed ID: 33489701
[TBL] [Abstract][Full Text] [Related]
8. Ovarian seromucinous tumors: clinicopathological features of 10 cases with a detailed review of the literature.
Idrees R; Din NU; Siddique S; Fatima S; Abdul-Ghafar J; Ahmad Z
J Ovarian Res; 2021 Mar; 14(1):47. PubMed ID: 33736662
[TBL] [Abstract][Full Text] [Related]
9. Mixed Ovarian Neoplasms With Gastrointestinal-type Mucinous and Mullerian Epithelial Components: A Rare Group of Tumors Demonstrating the Phenotypic Plasticity of the Mullerian Epithelial Cell.
Chui MH; Ellenson LH
Am J Surg Pathol; 2023 Jul; 47(7):756-765. PubMed ID: 37125505
[TBL] [Abstract][Full Text] [Related]
10. Ovarian Seromucinous Borderline Tumor and Clear Cell Carcinoma: An Unusual Combination.
Nakamura E; Sato Y; Moriguchi S; Yamashita A; Higo T; Asada Y
Case Rep Obstet Gynecol; 2015; 2015():690891. PubMed ID: 26075120
[TBL] [Abstract][Full Text] [Related]
11. PAX2, PAX8 and CDX2 Expression in Metastatic Mucinous, Primary Ovarian Mucinous and Seromucinous Tumors and Review of the Literature.
Ates Ozdemir D; Usubutun A
Pathol Oncol Res; 2016 Jul; 22(3):593-9. PubMed ID: 26797858
[TBL] [Abstract][Full Text] [Related]
12. Seromucinous Tumors of the Ovary. What's in a Name?
Kurman RJ; Shih IeM
Int J Gynecol Pathol; 2016 Jan; 35(1):78-81. PubMed ID: 26598986
[TBL] [Abstract][Full Text] [Related]
13. Loss of ARID1A expression is an early molecular event in tumor progression from ovarian endometriotic cyst to clear cell and endometrioid carcinoma.
Ayhan A; Mao TL; Seckin T; Wu CH; Guan B; Ogawa H; Futagami M; Mizukami H; Yokoyama Y; Kurman RJ; Shih IeM
Int J Gynecol Cancer; 2012 Oct; 22(8):1310-5. PubMed ID: 22976498
[TBL] [Abstract][Full Text] [Related]
14. Morphologic Reproducibility, Genotyping, and Immunohistochemical Profiling Do Not Support a Category of Seromucinous Carcinoma of the Ovary.
Rambau PF; McIntyre JB; Taylor J; Lee S; Ogilvie T; Sienko A; Morris D; Duggan MA; McCluggage WG; Köbel M
Am J Surg Pathol; 2017 May; 41(5):685-695. PubMed ID: 28125452
[TBL] [Abstract][Full Text] [Related]
15. Mutation Profiles of Ovarian Seromucinous Borderline Tumors in Japanese Patients.
Sasamori H; Nakayama K; Razia S; Yamashita H; Ishibashi T; Ishikawa M; Sato S; Nakayama S; Otsuki Y; Fujiwaki R; Ishikawa N; Kyo S
Curr Oncol; 2022 May; 29(5):3658-3667. PubMed ID: 35621684
[TBL] [Abstract][Full Text] [Related]
16. Comprehensive genomic profiling reveals ubiquitous KRAS mutations and frequent PIK3CA mutations in ovarian seromucinous borderline tumor.
Wu RC; Chen SJ; Chen HC; Tan KT; Jung SM; Lin CY; Chao AS; Huang KG; Chou HH; Chang TC; Chao A; Lai CH
Mod Pathol; 2020 Dec; 33(12):2534-2543. PubMed ID: 32616873
[TBL] [Abstract][Full Text] [Related]
17. Ovarian Seromucinous Borderline Tumors Are Histologically Different from Mucinous Borderline Tumors.
Hada T; Miyamoto M; Ishibashi H; Kawauchi H; Soyama H; Matsuura H; Sakamoto T; Kakimoto S; Aoyama T; Iwahashi H; Suzuki R; Tsuda H; Takano M
In Vivo; 2020; 34(3):1341-1346. PubMed ID: 32354928
[TBL] [Abstract][Full Text] [Related]
18. Seromucinous component in endometrioid endometrial carcinoma as a histological predictor of prognosis.
Miyamoto M; Takano M; Aoyama T; Soyama H; Yoshikawa T; Tsuda H; Furuya K
J Gynecol Oncol; 2018 Mar; 29(2):e20. PubMed ID: 29400013
[TBL] [Abstract][Full Text] [Related]
19. Ovarian atypical proliferative (borderline) mucinous tumors: gastrointestinal and seromucinous (endocervical-like) types are immunophenotypically distinctive.
Vang R; Gown AM; Barry TS; Wheeler DT; Ronnett BM
Int J Gynecol Pathol; 2006 Jan; 25(1):83-9. PubMed ID: 16306790
[TBL] [Abstract][Full Text] [Related]
20. Ovarian Clear Cell Tumors Associated With Seromucinous Borderline Tumor: A Case Series.
Vroobel KM; McCluggage WG
Int J Gynecol Pathol; 2022 Jan; 41(1):76-81. PubMed ID: 33741765
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
